As pharmacologic options for presbyopia continue to expand, clinicians must move beyond simplistic “small pupil” treatment paradigms toward a more individualized, lifestyle-driven approach to patient care. In this program, attendees will explore the differing mechanisms of action among emerging presbyopia therapies.

This program is supported by an independent medical educational grant from Mylan Inc., a Viatris Company.

Speaker: Cecelia Koetting, OD

Date: Tuesday, December 1, 2026

Time: 5:30 PM - 6:30 PM Pacific Time

Location: Virtual

Moderator: Pending

Cost: Free!

COPE ID: Pending

Category: Pending

This event is undergoing COPE approval for 1 hour CE credit.